Differential impact of antihypertensive drugs on cardiovascular remodeling: a review of findings and perspectives for HFpEF prevention

Seven‐action approaches for the management of hypertension in Asia – The HOPE Asia network

“…[86][87][88][89] Other sodium-excerting drugs such as angiotensin receptor-neprilysin inhibitors (ARNI) and sodium-glucose co-transporter 2 (SGLT2) inhibitors, both of which are proven therapies for heart failure, are also effective in lowering BP. [90][91][92][93][94][95][96][97] SGLT2 inhibitors also decrease 24-hour BP in patients who have both diabetes and hypertension. [98][99][100][101] ARNI have recently been launched for the treatment of hypertension in Japan and China.…”

“…Mineralocorticoid receptor (MR) blockers reduce potassium excrete and hence increase serum potassium, and the recently developed selective MR blocker, esaxerenone, has been shown to reduce nighttime and morning BP, and decrease levels of N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) 86–89 . Other sodium‐excerting drugs such as angiotensin receptor‐neprilysin inhibitors (ARNI) and sodium‐glucose co‐transporter 2 (SGLT2) inhibitors, both of which are proven therapies for heart failure, are also effective in lowering BP 90–97 . SGLT2 inhibitors also decrease 24‐hour BP in patients who have both diabetes and hypertension 98–101 …”

Update on Hypertension Research in 2021

“…Stages of HF are classified from A to D [ 41 ]. HF patients are also divided into patients with preserved ejection fraction (EF) (HFpEF), those with mildly reduced EF and those with reduced EF (HFrEF).…”

“…Persistent hypertension and increased arterial stiffness in stage A HF result in left ventricular (LV) hypertrophy (LVH), at which point it is classified as stage B HF. Although the etiology of HFpEF is diverse, patients with HFpEF have been reported to have a high prevalence of hypertension, which is closely associated with increased arterial stiffness, LVH and diastolic LV dysfunction [ 41 ].…”